Placental site trophoblastic tumor: a 17-year experience at the New England Trophoblastic Disease Center.
OBJECTIVE
We reviewed cases of placental site trophoblastic tumors from the New England Trophoblastic Disease Center (NETDC) database from 1982-1999 in an effort to identify prognostic factors for recurrent disease.


METHODS
A chart review was performed utilizing patients identified from the NETDC database. Data obtained included patient age at diagnosis, antecedent pregnancy, duration and extent of disease, presenting symptoms, pre- and posttreatment hCG levels, diagnostic and therapeutic procedures, treatment and outcome of patients. Statistical analysis was performed using Student's t test and chi(2) test when appropriate.


RESULTS
Thirteen patients were identified. All ultimately underwent hysterectomy although initial treatment of 1 patient was uterine resection. There were 5 recurrences (43%)--3 among the 9 patients who had no metastases on presentation (33%) and 2 of 3 patients who presented with metastases (66%). The 5 patients who recurred were among 8 who had received peri- or postoperative chemotherapy (62.5%). Treatment of recurrences included continued or alternate chemotherapy, radiotherapy, and/or excision of locally recurrent disease. Follow up time averaged 56.2 months (range 12-182 months). One of the 4 patients receiving chemotherapy < or =1 week after hysterectomy recurred, whereas all 4 patients who received chemotherapy 3 weeks or more after hysterectomy recurred. Uterine tumor volume was significantly greater, 154.1 cm(3), in patients with initial metastases versus 42.3 cm(3) in patients without initial metastases (P = 0.04). Mitotic index (P = 0.04) was significantly increased in patients who developed recurrent disease.


CONCLUSIONS
High mitotic index appears to be an adverse prognostic indicator for recurrence. Hysterectomy remains the mainstay of treatment. Chemotherapy is indicated for patients with metastases and may be indicated when the mitotic index is >5 mitoses/10 HPF. Radiation treatment may play a role in recurrent disease but must be evaluated on a case-by-case basis.
Feltmate
C M
CM
Division of Gynecologic Oncology, Brigham and Womens Hospital, Boston, Massachusetts 02115, USA.
Genest
D R
DR
Wise
L
L
Bernstein
M R
MR
Goldstein
D P
DP
Berkowitz
R S
RS
D000328:Adult; D017024:Chemotherapy, Adjuvant; D006063:Chorionic Gonadotropin / Q000097:blood; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000628:therapy; D011247:Pregnancy; D011379:Prognosis; D012307:Risk Factors; D016896:Treatment Outcome; D018245:Trophoblastic Tumor, Placental Site / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
D006063:Chorionic Gonadotropin